The treatments recommended by NICE are Roche’s RoActemra (tocilizumab) and Eli Lilly’s Olumiant (baricitinib), both indicated for use in a hospitalised setting in patients requiring supplemental oxygen, as well as Pfizer’s Paxlovid (tirmatrelvir plus ritonavir) for use in non-hospitalised settings.
Those not recommended at this stage are Regenerons’ casirivimab and imdevimab, Merck and Ridgeback’s molnupiravir, GSK and Vir Biotechnology’s sotrovimab, as well as Gilead’s remdesivir and AstraZeneca’s Evusheld (tixagevimab and cilgavimab).
